Evidence map›Paper›PMID 38227898›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime Merchan, Jeffrey C Goh and 27 more

Open access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 11 pooled it
57.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 11 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Trial
  13. Trial
  14. Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 13 countries.

Robert J MotzerMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6925-2327
Camillo PortaUniversity of Bari "A. Moro," Bari, Italy.
Masatoshi EtoKyushu University, Fukuoka, Japan.
Thomas PowlesThe Royal Free NHS Trust, London, United Kingdom.ORCID 0000-0001-7760-4724
Viktor GrünwaldUniversity Hospital Essen, Essen, Germany.ORCID 0000-0003-2083-7687
Thomas E HutsonTexas Oncology, Dallas, TX.ORCID 0000-0002-4529-4212
Boris AlekseevP.A. Herzen Moscow Oncological Research Institute, Moscow, Russia.
Sun Young RhaYonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.ORCID 0000-0002-2512-4531
Jaime MerchanUniversity of Miami Sylvester Comprehensive Cancer Center, Miami, FL.ORCID 0000-0003-3752-4134
Jeffrey C GohICON Research, South Brisbane & Queensland University of Technology, Brisbane, Queensland, Australia.ORCID 0000-0003-3103-146X
Aly-Khan A LalaniJuravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-9907-9112
Ugo De GiorgiIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.ORCID 0000-0001-7520-2908
Bohuslav MelicharPalacky University, and University Hospital Olomouc, Olomouc, Czech Republic.
Sung-Hoo HongSeoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.ORCID 0000-0002-1952-4010
Howard GurneyMacquarie University, Sydney, NSW, Australia.ORCID 0000-0003-0217-5261
María José Méndez-VidalMaimonides Institute for Biomedical research of Cordoba (IMIBIC) Hospital Universitario Reina Sofía, Medical Oncology Department, Córdoba, Spain.ORCID 0000-0002-7460-1859
Evgeny KopyltsovState Institution of Healthcare "Regional Clinical Oncology Dispensary," Omsk, Russia.
Sergei TjulandinN N Blokhin National Medical Research Center for Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.ORCID 0000-0001-9807-2229
Teresa Alonso GordoaHospital Universitario Ramón y Cajal, Madrid, Spain.ORCID 0000-0002-8966-7236
Vadim KozlovState budgetary Health Care Institution "Novosibirsk Regional Clinical Oncology Dispensary," Novosibirsk, Russia.
Anna AlyasovaPrevoljskiy Region Medical Centre, Novgorod, Russia.
Eric WinquistWestern University, London, Ontario, Canada.ORCID 0000-0002-8829-5979
Pablo MarotoHospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Miso KimSeoul National University Hospital, Seoul, South Korea.ORCID 0000-0002-4064-4199
Avivit PeerRambam Health Care Campus, Haifa, Israel.
Giuseppe ProcopioFondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy.ORCID 0000-0002-2498-402X
Toshio TakagiTokyo Women's Medical University, Tokyo, Japan.
Shirley WongWestern Health, Melbourne, Victoria, Australia.
Jens BedkeDepartment of Urology and Transplantation Surgery, Klinikum Stuttgart, Stuttgart, Germany.ORCID 0000-0003-2778-3108
Manuela SchmidingerDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Karla Rodriguez-LopezMerck & Co, Inc, Rahway, NJ.
Joseph BurgentsMerck & Co, Inc, Kenilworth, NJ.
Cixin HeEisai Inc, Nutley, NJ.
Chinyere E OkparaEisai Ltd, Hatfield, UK.ORCID 0000-0002-5621-9138
Jodi McKenzieEisai Inc, Nutley, NJ.ORCID 0000-0002-6345-1218
Toni K ChoueiriDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-9201-3217
CLEAR Trial Investigators
State Healthcare Institution "Regional Clinical Oncological Dispensary" · RUMemorial Sloan Kettering Cancer Center · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USHospital Universitario Ramón y Cajal · ESRambam Health Care Campus · ILWestern Health · AUWestern University · CADana-Farber Cancer Institute · USInstituto Maimónides de Investigación Biomédica de Córdoba · ESIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITKlinikum Stuttgart · DEKyushu University · JPMacquarie University · AUMinistry of Health of the Russian Federation · RUP.A. Hertzen Moscow Oncology Research Institute · RUQueensland University of Technology · AURoyal Free London NHS Foundation Trust · GBTexas Oncology · USThe Catholic University of Korea Seoul St. Mary's Hospital · KRTokyo Women's Medical University · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedCarcinoma, Renal CellKidney NeoplasmsPhenylurea CompoundsQuinolinesAntineoplastic Combined Chemotherapy ProtocolsHumansSunitinibSurvival AnalysisAntibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolinesSunitinib

Identifiers

PMID38227898
PMCPMC11095851
OpenAlexW4390902638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.